key: cord-0988876-kdv06ecc
authors: Baddock, Hannah T.; Brolih, Sanja; Yosaatmadja, Yuliana; Ratnaweera, Malitha; Bielinski, Marcin; Swift, Lonnie P.; Cruz-Migoni, Abimael; Morris, Garrett M.; Schofield, Christopher J.; Gileadi, Opher; McHugh, Peter J.
title: Characterisation of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification
date: 2020-08-13
journal: bioRxiv
DOI: 10.1101/2020.08.13.248211
sha: 1eee5874928d6b4b5580652e0f80a4d519a66b97
doc_id: 988876
cord_uid: kdv06ecc

The SARS-CoV-2 coronavirus (CoV) causes COVID-19, a current global pandemic. SARS-CoV-2 belongs to an order of Nidovirales with very large RNA genomes. It is proposed that the fidelity of CoV genome replication is aided by an RNA nuclease complex, formed of non-structural proteins 14 and 10 (nsp14-nsp10), an attractive target for antiviral inhibition. Here, we confirm that the SARS-CoV-2 nsp14-nsp10 complex is an RNase. Detailed functional characterisation reveals nsp14-nsp10 is a highly versatile nuclease capable of digesting a wide variety of RNA structures, including those with a blocked 3’-terminus. We propose that the role of nsp14-nsp10 in maintaining replication fidelity goes beyond classical proofreading and purges the nascent replicating RNA strand of a range of potentially replication terminating aberrations. Using the developed assays, we identify a series of drug and drug-like molecules that potently inhibit nsp14-nsp10, including the known Sars-Cov-2 major protease (Mpro) inhibitor ebselen and the HIV integrase inhibitor raltegravir, revealing the potential for bifunctional inhibitors in the treatment of COVID-19.

From late 2019 and throughout 2020 the SARS-CoV-2 virus, which causes the disease 3 COVID-19, has spread across the globe, to date infecting upwards of ten million 4 people and killing over half a million of these (coronavirus.jhu.edu). A detailed 5 understanding of the mechanistic aspects of this virus' life and infectivity cycle are 6 urgently required as are drugs that are able to curb its replication and virulence. 7 8 SARS-CoV-2 is a coronavirus (CoV), of the coronaviridae family in the Nidovirales 9 order. One characteristic of these CoVs is their (relatively) large single-stranded RNA 10 genomes (~30 kb in the case of SARS-CoV-2) 1 . Perhaps necessarily, CoVs typically 11 have a replication fidelity rate of an order of 10 -6 to 10 -7 , which is several orders of 12 magnitude more accurate than that of most RNA viruses (typically ~10 -3 to 10 -5 ) 2 . In 13 order to maintain the fidelity of these genomes during replication, CoVs rely upon a 14 complex of two non-structural proteins, nsp14 (also known as ExoN) and nsp10 [2] [3] [4] . 15

The importance of this enhanced level of replication fidelity has been demonstrated in 16 studies that disrupt or inactivate the activity of nsp14-nsp10, where reduced virulence 17 and pathogenesis is seen in mouse and cellular models [4] [5] [6] . Therefore, targeting nsp14-18 nsp10 is an attractive therapeutic strategy, either as a standalone option or as an 19 adjuvant to other agents that target other features of the replication cycle of the virus 7 . 20 21

The nsp14-nsp10 proteins form a complex where a ribonuclease activity is conferred 22 by the DEDD catalytic motif of nsp14, but where nsp10 plays a key role in conferring 23 full activity 3, 8, 9 . A study of the SARS-CoV-1 complex implied that its ribonuclease 24 activity is dsRNA selective 3 . This complex has been reported to possess 3′-5′ 25 exonuclease activity and, based on its ability to excise terminally mismatched 26 ribonucleotides, one function ascribed to nsp14-nsp10 (by analogy with replicative 27 DNA polymerases) is ′proofreading′ activity 3,10 , although other key roles in viral 28 replication have been postulated 11 . Consistent with a role in proofreading of 29 maintaining genome stability, nuclease-inactivating mutations in CoV DEDD motifs 30 cause an elevated level of replication errors, impaired replication and in some cases 31 lethal mutagenesis 4, 5, 12 . Moreover, nsp14 interacts with the CoV RNA-dependent RNA 32 polymerase (RdRp), (i.e. the nsp12 subunit of the nsp12-nsp7-nsp8 complex), 33

integrating the nuclease activities of nsp14 with the replicative process, although the 2 molecular details of this interaction remain only partly characterised 10,11 . The nsp14 3 protein also contains a functionally distinct (from its nuclease) SAM-dependent (S-4 adenosyl methionine) guanine-N7 methyl transferase (MTase) activity [13] [14] [15] . This 5 activity is required in the third step in production of the mature 5′-RNA CoV cap 6 structure (cap-1), methylating a 5′-5′ triphophosphate GpppN generating the cap-0 7 intermediate. 8

Here, we describe purification of the SARS-CoV-2 nsp14-nsp10 complex and detailed 10 characterisation of its nuclease activity and substrate profile. We find that the complex 11 is a highly versatile nuclease able to not only potentially able act in a proofreading 12 capacity, but which is also capable of processing a structurally diverse range of RNA 13 molecules, in both ssRNA and dsRNA. Notably, some of the activities observed do not 14 require a free 3′-OH group, implying that nsp14-nsp10 exhibits both exo-and 15 endonuclease like activities. We propose that nsp14-nsp10 could act broadly to 16 remove structures accumulating within the nascent replicating RNA strand that would 17 potentially affect high fidelity extension by the SARS-CoV-2 RNA-dependent RNA 18 polymerase (RdRp) 16 . We also used the assay systems we developed to screen for 19 inhibitors, identifying several drugs and drug-like molecules that might be repurposed 20 to inhibit the nuclease activity of this complex. 21

Employing codon optimised constructs expressed in E. coli, we purified the nsp14-25 nsp10 complex to near homogeneity (Fig. 1a) . The presence of faint protein bands 26 between the nsp14 and nsp10 proteins which were visible by SDS-PAGE were 27 confirmed to be nsp-14 degradation products by tryptic digest MS/MS analysis. The 28 complex eluted from the size-exclusion column with a volume consistent with a 29 heterodimer ( Supplementary Fig. 1a) , and the identity of the protein was confirmed by 30 intact mass spectrometry ( Supplementary Fig. 1b) . In addition to the wild-type protein, 31

we purified a control complex bearing substitutions at residues D113 and E115 32 (nsp14 D113A,E115A -nsp10) which by comparison with previously evaluated SARS-CoV-33 1 complex is expected to be catalytically inactive (Fig. 1a) 8 . Moreover, we purified the 2 nsp14 (ExoN) subunit alone to determine its individual activity (bacterial expressed 3 nsp10 rapidly precipitated in solution, presumably requiring association with nsp14 to 4 maintain solubility, as previously proposed 8 ) (Fig. 1a) . 5 6 Previous studies of the CoV nsp14-nsp10 complexes have been limited to the SARS-7

Cov-1 strain proteins 3, 9 . In the latter study, a preferential activity on double-stranded 8 DNA (dsRNA) over single-stranded DNA (ssRNA) combined with an enhanced 9 capacity to process substrates with mismatches within 4-ribonucleotides of a 3′-OH 10 was reported. For the Sars-CoV-2 complex, we performed an extensive evaluation of 11 RNA structures, sequences and modifications to comprehensively define the major 12 activities of the complex. We initially utilised a 20-mer ssRNA substrate radiolabelled 13 at the 5′-end. It has previously been reported that while nsp14 alone is active as a 14 nuclease, its activity is substantially increased by association with nsp10 3, 8 . To test 15 this, we incubated the ssRNA substrate with nsp14 alone, and the nsp14-nsp10 16 complex. Substrate digestion was observed for nsp14 at concentrations above 250 17 nM (on 10 nM of substrate). We confirmed that nsp10 dramatically enhances the 18 activities of nsp14, as efficient digestion by nsp14-nsp10 was observed at the lowest 19 concentration employed (15 nM) (Fig. 1b) . We next examined the activity of nsp14-20 nsp10 on sequence-related ssRNA substrates of varying length. Whilst no activity 21 could be observed with a 10-mer, possibly because this substrate is too short to permit 22 stable binding of the nsp14-nsp10 complex, robust activity at concentrations above 23 250 nM was observed with a 30-mer ( Supplementary Fig. 1c ). Moreover, for both the 24 20-mer and 30-mer substrates a complex digestion pattern was observed 25 ( Supplementary Fig. 1c ). We saw RNA laddering close to the 3′-terminus, consistent 26 with the previously reported 3′-exonuclease activity of this complex, but also several 27 additional prominent additional bands representing cleavage further from the 3′-end. 28

We next precisely identified the size of the major products released by the nsp14-29 nsp10 on the 20-mer substrate. In order to do this, we performed limited hydrolysis on 30 the 20-mer substrate to provide a single-nucleotide molecular weight marker 31 ( Supplementary Fig. 1d ). This enabled us to determine that the laddering products 32 observed at the top of the gel correspond to fragments digested in a single-nucleotide 33 6 fashion from the 3′-end, and that this processing terminates at the 8 th ribonucleotide 2 from the 3′-end (labelled with *). Two additional prominent bands were identified, 3 corresponding to cleaved 10 th and 13 th ribonucleotides from the 3′-end, releasing a 4 10-mer and 7-mer product (labelled on Fig. 1b and Supplementary Fig. 1d as ** and 5 ***, respectively). 6 7 We then confirmed that the activities we observed are intrinsic to the nsp14-nsp10 8 complex by two complementary methods. First, we purified the predicted nuclease 9

inactive complex nsp14 D113A,E115A -nsp10 and assayed its activity on the 20-mer 10 substrate. No activity was observed, even at concentrations 10-fold higher that the 11 highest concentration employed with the wild-type complex (5000 nM for 12 nsp14 D113A,E115A -nsp10 versus 500 nM for nsp14-nsp10; Fig. 1b ). Second, we ran the 13 wild-type nsp14-nsp10 complex on a gel filtration (size exclusion) column and then 14 assayed the eluted fractions for RNase activity. The elution profile of the heterodimeric 15 protein from this column precisely coincided with the peak in the characteristic RNase 16 activity we observe ( Supplementary Fig. 1e ), providing further reassurance that the 17 activities we are observe are intrinsic to the complex we have purified and not due to 18 a contaminant. 19 20 Finally, as previous biochemical and structural studies imply that the nuclease activity 21 of the ExoN family of nucleases is dependent upon divalent metal cations, we sought 22 evidence that this is the case for SARS-CoV-2 nsp14-nsp10 3, 8, 9 . First, we determined 23 which divalent cations support maximal activity of the complex. Both magnesium and 24 manganese promoted the RNase activity of nsp14-nsp10, whereas zinc was inhibitory 25 (Supplementary Fig. 2a . Consistent with a requirement for metal ions for activity, three 26 metal-chelating agents, EDTA, EGTA and ο-phenanthroline were strongly inhibitory, 27 with a particular sensitivity to EDTA ( Supplementary Fig. 2b) . For further studies, we 28 chose to perform reactions in the presence of magnesium as this efficiently supports 29 nsp14-nsp10 activity while being highly abundant in the mammalian cytoplasm. 30 31 32 33 observed at the highest concentration (500 nM). Together, these observations strongly 23

suggest that SARS-CoV-2 not only has a 3′-exonuclease activity, which is dependent 24 upon the presence of an unblocked 3′-RNA terminus (leading to the laddering 25 products we characteristically observe at the top of the gels), but also an 26 endonucleolytic activity, cleaving at positions further from the 3′-end. These incisions 27 occur independently of the presence of a 3′-hydroxyl or phosphate group, and 28 therefore do not require engagement with a 3′-terminus prior to initial exonucleolytic 29 processing at the 3′-terminus for their production. Interestingly, in the presence of 30 manganese the main cleavage product is the 7-mer, suggesting that this ion enhances 31 the endonuclease activity ( Supplementary Fig. 2a) . 32

To date, CoV nsp14-nsp10 complexes have been reported to act exclusively on RNA. 2

To confirm that this is the case for the Sar-CoV-2 complex, we compared the activity 3 of nsp14-nsp10 on our 20-mer ssRNA substrate with its activity on sequence-related 4 20-mer ssDNA and DNA:RNA hybrid substrates (where the DNA strand is 5′-5 radiolabelled) ( Supplementary Fig. 3a ). As expected, no activity was observed on 6 either DNA substrate. We also examined the ability of nsp14-nsp10 to act on substrate 7 containing a single ribonucleotide embedded within an 18-mer DNA duplex (3) (4) (5) (6) (7) (8) ribonucleotides form the 3′-end), analogous to the types of substrate processed by 9 ribonucleotide excision repair (RER) enzymes ( Supplementary Fig. 3a ) 18 . Some 10 activity was observed at concentrations above 125 nM with the two products released 11 being consistent with incisions being introduced 3′-and 5′-to the site of the embedded 12 ribonucleotide. While not necessarily physiologically relevant, this activity is 13 informative regarding the proposed endonucleolytic activity of this complex, since the 14 3′-DNA terminus of this substrate is completely resistant to nsp14-nsp10, but 15 nonetheless nsp14-nsp10 can cleave adjacent to the single embedded ribonucleotide. 16

It has been reported that the SARS-CoV-1 nsp14-nsp10 complex preferentially 19 degrades substrates containing mismatches of up to 4-ribonucleotides at their 3′-20 termini 3, 10 . To address this possibility for the SARS-CoV-2 complex, we generated 21 substrates containing 1-, 2-, 3-or 4-ribonucleotide mismatches at their 3′-termini, 22 where the 4-ribonucleotide mismatch effectively introduces a small 3′-flap allowing us 23 to examine the impact of this secondary structure on activity. We observed no 24 substantial difference in digestion efficiency across any of these four structures (Fig. 25 3b and quantified in Supplementary Fig. 3b ), although there were qualitative 26 differences in the major products released, likely reflecting differential modes of 27 association of the complex due to the structural variations in the substrates. We also 28 examined a substrate containing a single mismatch near its centre (8-ribonucleotides 29 from the 3′-end). This was also processed with an efficiency indistinguishable from 30 the other substrates, exhibiting a qualitative pattern of digestion similar to the 31 substrates containing the terminal mismatches ( Fig. 3b and quantified in 32 Supplementary Fig. 3b ). Taken together, our results show that mismatched termini are 33 not preferentially processed by the SARS-Co-V-2 nsp14-nsp10 complex, but rather 2 the complex is an exo-and endo-nuclease able to act on a wide variety of RNA 3 substrates, both single-and double-stranded. 4 5 Finally, we examined whether some common modifications of viral RNA impact the 6

RNase activity of nsp14-nsp10. We investigated the impact of 6-methyladenine, one 7 of the most common modifications found in cytoplasmic RNA, along with an artificial 8 base modification, 2-methyladenine. Importantly, 6-methyladenine modification has 9 been associated with viral evasion by the host innate immune system 19 . We also 10 examined the variant RNA base inosine, that can be generated by A-to-I editing and 11 has been reported to enhance viral recognition by the innate immune sensors 20 . When 12 any of these modified bases was placed two ribonucleotides from the 3′-terminus of 13 the 20-mer substrate, none affected, either qualitatively or quantitatively, activity of 14 nsp14-nsp10 when compared with a native (unmodified) RNA substrate 15 ( Supplementary Fig. 3c ). We conclude that some common chemical modifications of 16 RNA do not substantially affect nsp14-nsp10 RNase activity. 17

The urgent need to identify therapeutics to treat COVID-19 then led us to scope 20 potential nsp14-nsp10 inhibitors, with a focus on compounds identified as potential 21 COVID-19 treatments and known nuclease inhibitors. Previous studies suggest that 22 inactivation of nsp14-nsp10 can lead to increased genomic instability and therefore a 23 potentially lethal mutagenesis and concomitant reduction in viral propagation. While 24 this alone might be insufficient to treat COVID-19 effectively, the possibility that nsp14-25 nsp10 inhibitors could be combined with inhibitors of other key factors (for example, 26 the major proteases 3CL pro /M pro or replicative RNA polymerase catalytic subunit 27 nsp12) merits exploration. 28

Based on the efforts of ourselves and others to identify inhibitors of RNA and DNA 30 nucleases, we first performed in silico docking experiments focusing on chemotypes 31 known to inhibit nucleases. We employed the AutoDock Vina 21 platform to dock in-32 house compounds on the entire exposed surface (blind docking) and the surface 33 centred on the active site of a structure of SARS-CoV-1 nsp14-10 (PDB:5NFY) 10 . Use 2 of a homology model of SARS-CoV-2 nsp14-nsp10 created using PDB:5NFY was 3 considered inappropriate due to the low resolution of this structure. The docking 4

analyses revealed a range of pharmacophores that may interact with the enzyme 5 ( Supplementary Fig. 4a ), and one of these, an N-hydroxyimide compound (denoted 6 A-1) was identified as potentially interacting with the nsp14-nsp10 active site ( Fig. 5a ; 7

Efforts to establish a quantitative fluorogenic assay for nsp14-nsp10 activity, 10 analogous to those we and others have devised for endo-and exonucleases 11 previously 22 , have as yet been unsuccessful due to the exquisite sensitivity of the 12 nsp14-nsp10 complex to substrate modification by all fluor and quench moieties 13 tested. We therefore utilised a gel-based nuclease assay employing the 20-mer 14 ssRNA described above to examine the potential inhibitory characteristics of the 15 compound A-1, and its positional isomer A-2, available to us from existing chemical 16 libraries. The chemical aurintricarboxylic acid (ATA), which is a promiscuous 17 ribonuclease inhibitor used during nucleic acid extraction protocols was used as a 18 positive control 23 ; as expected, inhibited nsp14-nsp10 with an IC50 of 7.6 ± 1.1 μM 19 ( Fig. 4 ; Supplementary Fig. 5 ). Fig. 4a shows the inhibitory characteristics of A-1 and 20

A-2 N-hydroxyimides in the gel-based assay, each of which exhibit qualitatively 21 complete inhibition of substrate digestion (Fig. 4a) . Quantification of the gel-based 22 nuclease assay data did not yield an IC50 value for A-1, however, for A-2 this was 23 determined to be 20 ± 0.5 μM (Fig. 4b, Supplementary Fig. 5 ). Based on the docking 24 data of A-1 and potency of A-2 in the gel-based assay, we synthesised three structural 25 variants of these compounds. We decided to remove one of the rings, and use a 26 bicyclic hydroxyimide scaffold, as has previously been used against the nucleases 27 FEN1 and XPF-ERCC1 24,25 ; these compounds were denoted A-3 and A-4. We also 28 attempted to introduce a thiocarbonyl (A-5) to examine the potential effects on 29 inhibition ( Supplementary Fig. 6 ). However, none of these exhibited a lower IC50, and 30 therefore greater potency than A-2 ( Fig. 4 ; Supplementary Fig. 6 ). It is important to 31 note that due to nature of the gel-based assay, and the quality of the curves extracted, 32

that the absolute IC50 values should be regarded as preliminary, though complete 33 inhibition of nuclease activity is observed for A-1, A-2, A-3, B-1 and raltegravir at 2 concentrations of 100 µM. The N-hydroxyimide pharmacophore based is reported to inhibit structure-selective 5 DNA nucleases, via chelation of an active site metal ion(s) (particularly Mg 2+ ) 24,25 . Our 6 in silico docking shows potential for N-hydroxyimide compound binding at the nsp14-7 10 active site, with polar inhibitor atoms positioned close to the catalytic Mg 2+ ; wherein 8 for A-1 two of the hydroxyimide oxygen atoms are a distances of 2.4 Å and 2.6 Å from 9 the Mg 2+ (Fig. 5A) .The crystal structure of the human FEN1 nuclease with an N-10 hydroxyimide-based compound, AZ13623940 (denoted AZ-B1), bound to the active 11 site has previously been reported (PDB: 5FV7) 26 . To allow possible mechanistic 12 insight, the docking pose of AZ-B1 and its interaction with the catalytic Mg 2+ in the 13 nsp14-nsp10 model was compared with a structure of FEN1 in complex with AZ-B1 14 ( Fig. 5b) . While there was little overlap of the highest predicted affinity active site-15 docked pose of AZ-B1 with the AZ-B1 binding mode in the FEN1 structure, the fourth 16 pose did align well with the Mg 2+ of nsp14-nsp10, close to a FEN1 Mg 2+ (Fig. 5b) , also 17 validating the ability of AutoDock Vina to place compounds near divalent metal ions. 18

Taking advantage of previous identification and detailed characterisation of a series 20 of FEN-1 inhibitors 26 , we determined whether this molecule (AZ-B1), and AZ1353160 21 (denoted AZ-A1) are also capable of inhibiting SARS-CoV-2 nsp14-nsp10. While 22 some inhibition was observed ( Supplementary Fig. 7 ), these were also inferior to A-2. 23

The N-hydroxypyrimidinone ring is structurally similar to N-hydroxyimide and 25 hydroxypyrimidinones inhibit nucleases through binding to the active site metal ion(s), 26

typically Mg 2+27,28 . Therefore, we tested the commercially available compound 5,6-27 dihydroxyl-2-phenylpyrimidine-4-carboxylic acid (denoted B-1). B-1 exhibited a 28 comparable inhibition profile to A-2 with an IC50 value of 32. 2 ± 4.5 μM (Fig. 4; 29 Supplementary Fig. 5) . We also tested raltegravir, an HIV integrase inhibitor, which 30 contains a hydroxypyrimidinone ring 27,28 . Similar to B-1, raltegravir exhibited clear 31 inhibition of the exonuclease activity of nsp14-nsp10 with an IC50 value of 24.4 ± 2.7 32 μM ( Fig. 4; Supplementary Fig. 5 ). Our in silico approach modelled B-1 docked 33 proximal to the active site of nsp14-nsp10, with an oxygen atom of the 2 hydroxypyrimidinone coordinating the catalytic Mg 2+ , at a distance of 2.7 Å (Fig. 5c) . 3

Docking shows B-1 can bind at the active site of nsp14-10, with an oxygen atom of 4 the hydroxypyrimidinone coordinating the catalytic Mg 2+ ( 2.7 Å) (Fig. 5c ). The docked 5 pose of raltegravir differed from that of B-1, however, it was again positioned close to 6 the active site Mg 2+ , making additional contacts within the putative substrate binding 7 pocket (Fig. 5D ). 8

These experiments provided important insight into pharmacophores that may be 10 further developed and tested as COVID-19 treatments. However, the urgency of 11 addressing COVID-19 requires that experimental or approved drugs can be 12 repurposed for treatment. We therefore undertook at low-throughput (limited by the 13 lack of a scalable fluorescent assay) screen of candidate drugs that might be 14 predicted, on the basis of their mechanism of action, to inhibit the nuclease activity of 15 nsp14-nsp10. These included nucleoside analogues, topoisomerase poisons, 16 candidate DNA repair inhibitors, compounds reported to inhibit other COVID-19 17 targets and antivirals believed to interfere with nucleic acid metabolism. The 18 compounds tested and the results from the gel-based nuclease assay screening are 19 summarised in Supplementary Table 2 ). Of these, ebselen (an organoselenium 20 molecule with broad pharmacological properties 29,30 and a known potent inhibitor of 21 the main CoV protease 3CL pro ) and disulfuram (a carbothioamide used to treat alcohol 22 dependence 31 ) appeared most active in our screen. Detailed analysis allowed us to 23 determine that the IC50 for ebselen and disulfuram are 3.3 ± 0.09 μM and 89 ± 33 μM, 24 respectively ( Fig. 6 and Supplementary Fig. 5 ). We also included thiram, a non-drug 25 compound (used as a fungicide) which is also a carbothioamide related to disulfuram 26 to determine whether this chemotype more generally acts to inhibit nsp14-nsp10. The 27 IC50 for thiram was 48.2 ± 1.8 µM, suggesting that further surveys of carbothioamides 28 are warranted in the search for nsp14-nsp10 inhibitors. 29

To ensure the compounds that exhibited inhibitory effects were not exerting these 31 through aggregation or precipitation of nsp14-nsp10, we employed differential 32 scanning fluorimetry (DSF) under identical reaction conditions to the inhibitor nuclease 33 assays. None of the inhibitors showed any destabilising effect on thermal stability of 2 nsp14-nsp10, with the exception of ATA at higher concentrations ( Supplementary Fig.  3 

Ebselen has generally well-tolerated in clinical studies investigating its effectiveness 6

for treating a range of conditions from stroke and hearing loss to bipolar disorder 29 . 7

One mechanism of action proposed for ebselen relates to the potential capacity of the 8 selenium to react with the thiolate ligands of zinc clusters in proteins and to release 9 zinc 32-35 . To test whether the selenium is critical for the inhibition of nsp14-nsp10 10 nuclease activity, we investigated an analogue of this molecule, PBIT, where a sulphur 11 atom replaces the selenium. Consistent with an important role for the selenium in 12 nsp14-nsp10 inhibition, PBIT demonstrated a dramatically reduced potency of 13 inhibition (Fig. 6a ). We conclude that the best, potentially clinically useful nsp14-nsp10 14 inhibitor we have identified is the M pro inhibitor ebselen, where the selenium moiety 15 plays an important role mediating its inhibitory effects. 16 17 In conjunction with our low-throughput nuclease assay inhibitor screening, all 18 compounds tested were screened for binding to SARS-CoV-1 nsp14-nsp10 using Here we present the first biochemical analysis of the nsp14-nsp10 protein complex, 3 that plays a key role in the genome duplication of the SARS-CoV-2 virus, the causative 4 agent for COVID-19. Previous studies of the related SARS-CoV-1 complex have 5 primarily focused on structural aspects 8, 10 . The 3′-exonuclease activity of the CoV-1 6 was complex was reported, but it was not subject to detailed biochemical analysis. 7 8

Our study confirms the presence of a 3′-exonuclease activity in the Cov-2 nsp14-9 nsp10 complex, which is curtailed when the 3′-hydroxyl terminus of the RNA substrate 10 is changed to a biotin group. Altering the nature of the 3′-terminus, however, revealed 11 a further feature of nsp14-nsp10 activity, i.e. the capacity of the enzyme complex to 12 catalyse incisions further into (closer to the 5′-end) of the substrate. We observed a 13 robust and almost equivalent activity of nsp14-nsp10 on both ssRNA and dsRNA. 14 Related, we did not observe preferential excision of terminally mismatched nucleotides 15 by the CoV-2 nsp14-nsp10 complex, as has been reported for the analogue CoV-1 16 complex 3 . Instead, therefore, we observed that nsp14-nsp10 is capable of degrading 17 (approximately) the first eight ribonucleotides from the 3′-end of all substrates tested 18 (either ssRNA or dsRNA) in an exonucleolytic fashion. When a 3′-hydroxyl group was 19 not present the nsp14-nsp10 nuclease acted further downstream (5′-to) these sites to 20 endonucleolytically release fragments of 7-to 10-ribonucleotides endonucleolytically. 21

We therefore propose that the role of nsp14-nsp10 is more than that of a proof-reader, 22

by the analogy to the 3′-exonuclease present in replicative DNA polymerase 23 complexes 11 . We propose nsp14-nsp10 might represent a simple replication-repair 24 system potentially capable of removing ribonucleotides from the 3′-end of elongating 25

replicating RNA strand when extension is blocked. It is likely that the activity of the 26 nsp14-nsp10 is constitutively active during viral replication. It is possible that only 27 when replication stalls due to mismatch incorporation or the presence of altered 28 ribonucleotides that cannot be further extended by the polymerase, the nuclease 29 degrades and/or cleaves the elongating strand, so removing the aberration and 30

allowing for re-engagement of the RNA polymerase and resumption of synthesis. It 31 will be important to reconstitute this replication-repair reaction in future studies to test 32 this hypothesis. We note that another key feature of nsp14-nsp10 nuclease activity is 33 its insensitivity to common RNA modifications that are associated with viral evasion 2 (6-methyladenine) or induction (inosine) of innate immune pathways. 3 4 An important question pertains to why we have observed catalytic activities not 5 previously reported in the analyses of CoV-1 nsp14-nsp10. We tentatively propose an 6 explanation based on our experience of working with nsp14-nsp10, namely that the 7 purified complex is exceptionally unstable under frozen storage, even after a period 8 as short as one week. The assays presented here were all performed on nsp14-nsp10 9 that was less than one week old; after this time elapsed, we found that its activity 10 diminished dramatically, and its behaviour altered. It is possible that degradation 11 and/or aggregation both reduces nsp14-nsp10 activity and alters its substrate 12 selectivity. It is notable that the protein concentrations we employed in our assays, 13

and which supported good activity on ssRNA and dsRNA substrates (15 nM), were far 14 lower than those employed in previous studies that reported on the activity of the CoV-15 1 complex (several hundred nM), consistent with this suggestion 3, 8 . 16 17 Due to the urgency of identifying new drugs and candidate agents that can treat 18 COVID-19, we also performed both an in silico docking screen to identify chemotypes 19 capable of interacting with the metal-containing active site of nsp14, and a focused 20 screen of drugs (approved and in development) that might inhibit nsp14-nsp10. Our 21 docking simulations, employing structural data for the highly homologous Co-V nsp14-22 nsp10 complex, revealed that both N-hydroxyimide based compounds could 23 potentially interact with the active site magnesium ion. Testing supported this 24 possibility, revealing one compound from a library available to us, A-2 with an IC50 of 25 20.7 ± 0.5 µM. In the limited time available, we were able to generate several chemical 26 variants around this pharmacophore, but none to date out-performed A-2, nor did two 27 related compounds previously developed to inhibit the FEN-1 DNA nuclease 26 . We 28 expanded our search to explore the putative inhibitory potential of a 29 hydroxypyrimidone scaffold. Compound B-1 exhibited comparable levels of inhibition 30 to the N-hydroxyimide based compounds, as did the HIV integrase inhibitor, 31 raltegravir, with IC50 values of 32.3 ± 4.5 µM and 24.4 ± 2.7 µM, respectively. 32 33 Using docking we were able to model binding of A-1,3-5, B-1, and raltegravir to nsp14-2 nsp10 using with the structure of SARS-Cov-1. In accordance with previous literature, 3

the N-hydroxyimide and hydroxypyrimidone scaffolds chelated the active site 4 magnesium ion of the SARS-Cov nsp14-nsp10 24,26 , thus providing insight into the 5 possible mode of inhibition. Interestingly, the in silico modelling with raltegravir 6

suggests the larger compound could be accommodated well in the active site pocket, 7 potentially making additional contacts, which has the possibility of being explored 8 and/or exploited in future approaches to generate targeted inhibitors of nsp14-nsp10. 9

10 Our focused screens of drug and drug candidates with predicted potential to interact 11 with or inhibit nucleic acids processing enzymes revealed that the selenium-containing 12 drug ebselen was an effective inhibitor of nsp14-nsp10. It is interesting to note that interactions with the RNA viral genome 8, 10 . Interference with these zinc atoms from 25 these binding motifs might induce conformational changes that are not compatible with 26 robust activity. Given that ebselen is capable of targeting two key enzymes required 27 for the propagation of SARS-CoV-2, it is reasonable that further studies assessing the 28 utility of this agent in combatting COVID-19, as a stand-alone agent or in combination, 29 are warranted. More generally, given that many important antimicrobial medicines act 30 by binding to multiple targets (e.g. b-lactams such as penicillin and cephalosporins), 31

we suggest that polypharmacology be pursued as a matter of priority for COVID-19 32 treatment. 33

Expression and purification of wildtype and nuclease dead (NSP14 D113A/E115A ) 3

The N-terminally His-tagged nsp14-10 protein complex was expressed as a bi-5 cistronic mRNA in which nsp14 bearing a N-terminal Histidine tag is followed by a 6 ribosome binding site and the untagged nsp10 ORF. The protein was generated by The cleaved nsp14-10 complex was concentrated to 1 mL using a 50 kDa MWCO 31 centrifugal concentrator. The protein was then further purified on to a Superdex 200 32 increase 10/300 GL column equilibrated with SEC buffer (25 mM HEPES pH 7.5, 150 33 mM NaCl, 5% v/v glycerol, 2 mM TCEP) at 0.8 mL/min. The purified protein was 2 concentrated to 0.5 mg mL -1 and was snap frozen in liquid nitrogen for later use. (95% formamide, 10 mM EDTA, 0.25% xylene cyanol, 0.25% bromophenol blue) was 27 added to each sample, samples were combined and run on a 20% denaturing 28 polyacrylamide gel (40% solution of 19:1 acrylamide:bis-acrylamide, BioRad) and 7 M 29 urea (Sigma Aldrich)) in 1 x TBE (Tris-borate EDTA) buffer. Electrophoresis was 30 carried out at 525 V for 1.5 hours; gels were subsequently fixed for 60 min in fixing 31 solution (50% methanol, 10% acetic acid), and dried at 80 o C for two hours under a 32 20 vacuum. The dried gels were exposed to a Kodak phosphorimager screen and 2 scanned using a Typhoon 9400 instrument (GE). 3 4

Nuclease assays were carried out in 10 μL reactions containing 25 mM HEPES-KOH, 6 pH 7.5, 50 mM NaCl, 5 mM MgCl2, 5% glycerol, 1.0 mM DTT, 10 nM RNA or DNA 7 substrate and serially diluted two-fold nsp14-nsp10 complex or nsp14 from 500 nM. dried gels were exposed to a Kodak phosphorimager screen and scanned using a 18

Typhoon 9400 instrument (GE). 19 20 Where applicable, gel-based nuclease assays were quantified by analysing the 21 product formation (digestion) of the radiolabelled RNA substrate(s). Gel images 22 collected on a Typhoon scanner were analysed in Image J to determine the amount 23 of substrate remaining in the well (undigested) in comparison to the amount of 24 substrate that entered the gel (product) reported as a percent digested. This was 25 plotted versus protein concentration to indicate digestion rate. Error is standard error. 26

Three or more gels were analysed for each substrate. 27 28

Inhibitor exonuclease assays were carried out in 10 μL volumes containing 25 mM 30 HEPES-KOH, pH 7.5, 50 mM NaCl, 5 mM MgCl2, 5% glycerol, 1.0 mM DTT and 100 31 nM nsp14-10. Inhibitors were solubilised in DMSO and diluted immediately prior to the 32 reaction in the above buffer. Inhibitors were serially diluted two-fold from 100 μM and 33 the DMSO concentration was keep constant at 0.1% in the final reaction. Inhibitors 2 were incubated for 10 min at room temperature with the nsp14-10 complex, before the 3 reactions were initiated by the addition of RNA substrate (10 nM), incubated at 37 o C 4 for 45 min, then quenched by the addition of 5 μL stop solution (95% formamide, 10 5 mM EDTA, 0.25% xylene cyanol, 0.25% bromophenol blue) and boiling at 95 o C for 3 6 min. Reactions were analysed by 20% denaturing PAGE, fixed, dried, then imaged as 7 described above. to be 30 Å x 24 Å x 24 Å centred on (-5.196, -9.373, -7.837 (a) SDS-PAGE gel of purified nsp14 alone and WT nsp14-nsp10 (nsp14-nsp10) and a control 'nuclease-dead' complex bearing Ala-substitutions at D113 and E115 (nsp14 D113A,E115A -nsp10) showing the purity of the purified proteins. Predicted molecular weights are 59 463 Da for nsp14 and 15 281 Da for nsp10. (b) Nsp14-nsp10 is an RNase that digests a 20-mer ssRNA oligo (oligo 2 as indicated in Suppl. Table 1A ) in a single-nucleotide fashion from the 3'-end terminating at the 8 th ribonucleotide from the 3'-end (labelled *); it further incises closer to the 5'-end to generate 10-mer and 7mer products (labelled ** and *** respectively). Nsp14 alone can generate the 12-mer and 10-mer products, but when using significantly higher protein concentrations. The predicted nuclease-dead nsp14 D113A,E115A -nsp10 mutant complex exhibits no discernible nuclease activity, even at ten-fold higher concentrations compared with the wildtype complex. Increasing concentrations of protein (as indicated) were incubated with substrate at 37 o C for 45 min and reactions were subsequently analysed by 20% denaturing PAGE to visualize product formation. Size of products was determined as shown in Suppl. Fig 1D. Main products are labelled *, ** and *** corresponding to 12-mer, 10-mer and 7-mer respectively. (a) Nsp14-nsp10 nuclease activity is not sequence specific. The complex shows indistinguishable digestion patterns on two 20-mer ssRNA substrates of mixed sequence and containing all four bases. Oligos 2 and 3 were used, respectively (see Suppl. Table 1A ). (b) When presented with 20-mer Poly(U) and Poly(A) ssRNA (oligos 13 and 14 respectively;

Suppl. Table 1A ), nsp14-nsp10 shows reduced and qualitatively altered activity, with a single nucleotide step-wise digestion from the 3'-end curtailing at the 9 th -11 th nucleotide from the 3'end. (c) Nsp14-nsp10 processes ssRNA, the RNA strand of an RNA:DNA hybrid, and dsRNA with no preference for double-stranded substrates. For all structures, the labelled strand is oligo 2, also used in Fig. 1b (see Suppl. Table 1A and B). (d) Product formation (%) was quantified for Fig. 2 C comparing nsp14-nsp10 nuclease activity on ssRNA, the RNA strand of an RNA:DNA hybrid and dsRNA as outlined in Methods and Materials. All data are shown as mean ± s.e.m, and at least three biological replicates were used for each substrate. Nsp14-nsp10 shows equivalent activity on ssRNA and the RNA strand of an RNA:DNA hybrid with a slight decrease in activity for dsRNA.

Increasing concentrations of protein (as indicated) were incubated with substrate at 37 o C for 45 min; reactions were subsequently analysed by 20% denaturing PAGE to visualize product formation. The s of products was determined as shown in Suppl. Fig 1D. Main products are labelled *, ** and *** corresponding to 12-mer, 10-mer and 7-mer respectively. (a) Nsp14-nsp10 is an RNA exo-and endo-nuclease. With a substrate containing a 3´-biotin group, the characteristic laddering of the substrate is lost and only endonucleolytic cleavage at the positions furthest from the 3´-end is observed. Substrates with a 3´-hydroxyl or phosphate group, exhibit near identical product profiles. (b) Nsp14-nsp10 is an exo-and endo-nuclease able to incise a variety of RNA substrates, including RNA substrates with mismatched termini and flaps with no preference for mismatched ribonucleotides. Quantification in suppl. Fig. 3B (mm: mismatch, int. mm: internal mismatch).

Increasing concentrations of protein (as indicated) were incubated with substrate at 37 o C for 45 min; reactions were subsequently analysed by 20% denaturing PAGE to visualize product formation. Size of products was determined as shown in Suppl. Fig 1D. Main products are labelled *, ** and *** corresponding to 12-mer, 10-mer and 7-mer respectively. All oligos used are indicated in Suppl. (a) Size exclusion chromatogram for nsp14 alone, wild-type nsp14-nsp10 (designated nsp14-nsp10), and a control 'nuclease-dead' complex bearing alanine substitutions at residues D113 and E115 (nsp14 D113A,E115A -nsp10). Traces of Superdex 200 16/60 runs are shown for Nsp14 alone and wild-type nsp14-nsp10 and trace of Superdex increase 10/300 run for the 'nucleasedead' complex. Wild-type nsp14-nsp10 complex elutes in a single peak at ~82.5 mL, Nsp14 alone at ~84.3 mL and 'nuclease-dead' complex at ~14.6 mL . SDS-PAGE analysis of the fraction across the peak confirms the presence of both nsp14 and nsp10 in fractions D1-D8 (see Suppl. Fig. 1e ).

(b) Intact mass spectrometry analysis of nsp14 alone, wild-type nsp14-nsp10 (designated nsp14-nsp10) and a control 'nuclease-dead' complex bearing substitutions at residues D113 and E115 (nsp14 D113A,E115A -nsp10). LC-MS chromatogram shows the observed mass of all proteins is within range of the calculated mass.

(c) Nsp14-nsp10 digests 20-mer and a 30-mer ssRNA substrates, but not a 10-mer ssRNA.

(d) Nsp14-nsp10 is an RNA nuclease manifests a complex digestion pattern, digesting from the 3' end in a single-nucleotide fashion until the 8 th ribonucleotide, then cleaving at the 10 th and 13 th ribonucleotide. A single nucleotide ladder was used to determine the size of the released products.

(e) SDS-PAGE of the fractions before, during and after the peak used from gel filtration for wildtype nsp14-nsp10. The elution peak (D1-D8) coincides precisely with the characteristic RNAse activity that we observe in our activity gel. The predicted molecular weight is 59 463 Da for nsp14 and 15 281 Da for nsp10. Increasing concentrations of protein (as indicated) were incubated with substrate at 37 o C for 45 min, reactions were subsequently analysed by 20% denaturing PAGE to visualize product formation. The size of products was determined as shown in Suppl. Fig 1D. Main products are labelled *, ** and *** corresponding to 12-mer, 10-mer and 7-mer respectively. All oligos used are indicated in Suppl. Suppl. Figure 2 : Nsp14-nsp10 is metal-ion dependent RNA nuclease.

(a) Nsp14-nsp10 activity is enhanced by the addition of both MgCl2 and MnCl2, but is inhibited by ZnCl2. We determined 5 mM MgCl2 as optimal for activity. (b) Consistent with its requirement for metal ions, nsp14-nsp10 activity is inhibited by the addition of metal ion chelators EDTA, EGTA, and ο-phenanthroline, with a particular sensitivity towards EDTA.

125 nM or 250 nM of protein was incubated with increasing concentrations of ions or chelators (as indicated) on ice for 15 min before adding substrate and incubating the reaction at 37 o C for 45 min. Reactions were subsequently analysed by 20% denaturing PAGE to visualize product formation. For Suppl. Figs Figure 3 : Nsp14-nsp10 activity is specific to RNA only and is able to process common chemical modifications on RNA.

(a) Nsp14-nsp10 has no discernible nuclease activity on ssDNA or the DNA strand of an DNA:RNA hybrid. Interestingly, the complex is able to incise around an embedded ribonucleotide in a ssDNA oligo at concentrations above 125 nM.

(b) Product formation (%) was quantified for Fig. 3 B comparing nsp14-nsp10 nuclease activity on dsRNA and RNA substrates containing termini and internal mismatches as outlined in Methods and Materials. All data are shown as mean ± s.e.m, and at least three biological replicates were used for each substrate. Nsp14-nsp10 shows no preference for mismatched oligonucleotides compared to dsRNA. mm: mismatch int. mm: internal mismatch (c) Nsp14-nsp10 is able process common chemical modifications of RNA, namely 2methyladenine (m 2 A), 6-methyladenine (m 6 A) and inosine (I), both ssRNA and dsRNA with no apparent change compared to ssRNA or dsRNA.

Increasing concentrations of protein (as indicated) were incubated with substrate at 37 o C for 45 min, reactions were subsequently analysed by 20% denaturing PAGE to visualize product formation. The size of products was determined as shown in Suppl. Fig 1D. Main products are labelled *, ** and *** corresponding to 12-mer, 10-mer and 7-mer respectively. Oligomer substrates are in Suppl. Table 1A and B. Suppl. Figure 5 : Inhibition profile curves generated from gel-based nuclease assay data with the indicated compounds Inhibition profile curves were calculated by quantification of gel-based nuclease assay data as outlined in Methods and Materials. A decrease in the '% digested' of the substrate represents an increase in inhibition. Data were plotted against log10 of [inhibitor] and dose response curves were generated using non-linear regression. Where possible IC50 values were obtained. All data are shown as mean ± sem; t least three biological replicates were used for each compound. In some cases an IC50 value was unable to be calculated, either due to incomplete inhibition, or the inability to fit a sigmoidal curve to the data.

Suppl. Figure 6 

Suppl. Figure 7 

Increasing concentrations (as indicated, in μM) of indicated compounds were incubated with 100 nM nsp14-nsp10 for 10 minutes at room temperature, before starting a standard nuclease assay reaction by the addition of ssRNA, incubating at 37 o C for 45 min. Reaction products were analysed by 20% denaturing PAGE. A decrease in the generation of nucleolytic reaction products and a concomitant increase in undigested substrate indicates inhibition of nuclease activity at increasing inhibitor concentrations. -indicates no enzyme. Compound structures, functional groupings, and FDA approval status are shown alongside in vitro inhibition activity and AutoDock Vina scores of the highest-affinity binding modes for each compound. See Fig. 4, Fig. 5, Fig. 6 , Suppl. Fig. 4 , Suppl. Fig. 5 , Suppl. Fig. 7 , Suppl. Fig. 8 for relevant data.

Cloning and site directed mutagenesis of wildtype and nuclease dead (NSP14 D113A/E115A ) NSP14-10 complex.

Wildtype (WT) NSP14 and NSP10 encoding DNA were codon-optimised for

Escherichia coli (E. coli) expression and were synthesised by Twist Bioscience (California, USA). Both the NSP14 and NSP10 genes were subcloned into the pNIC28-BSA4 vector 1 to enable bicistronic expression and appropriately stoichiometric production of NSP14 and NSP10 proteins.

Site-directed-mutagenesis (SDM) was carried out using an 'inverse' PCR experiment,

whereby an entire plasmid is amplified using complementary mutagenic primers with minimal cloning steps 2 . The Herculase II Fusion DNA Polymerase (Agilent) was utilised and SDM PCR was performed to amplify the whole plasmid, according to the manufacturers instructions. The PCR product was then added to a standard KLD enzyme mix (NEB) reaction and was incubated at room temperature for 1 hour, prior to transformation into chemically competent E. coli cells.

All reagents were from Sigma-Aldrich, Acros Organics, Fluka, Fluorochem, Abcr, or Fisher Scientific and used without further purification. Flash column chromatography was performed using a Biotage Isolera automated flash column chromatography platform using Biotage KP-SNAP-Sil or SNAP Ultra columns. IR spectra were recorded using a Bruker Tensor 27 FT-IR spectrometer in the solid state or as a thin film. Selected characteristic peaks are reported in cm -1 . NMR spectra were recorded using Bruker Avance spectrometers in the deuterated solvent stated. Assignments given correspond with the numbering system as drawn; where assignments are not

given it was not possible to assign the resonances due to overlapping signals. Lowresolution mass spectra were recorded using an Agilent Technologies 1260 Infinity LC-MS system fitted with a 6120 Quadrupole mass spectrometer.

High-resolution mass spectra (HRMS) were recorded in HPLC grade methanol using electrospray ionisation (ESI+) on a Bruker APEX III FT-ICR mass spectrometer.

To stirred solution of 6-bromo-benzo[de]isochromene-1,3-dione (300 mg, 1.08 mmol)

in anhydrous pyridine (10 ml 

To stirred solution of 1 (360 mg, 0.94 mmol) and CuSO4 (10 mg 

)H), 7.72 (dd, J = 8.4, 7.3 Hz, 1H, C(1)H), 7.69 (dd, J = 7.8, 1.7 Hz, 2H, OBn(17) ArH2), 7.46 -7.33 (m, 3H, OBn(17) ArH3)

Hydroxy-6-methoxy-benzo

The reaction was then stirred for 4 h at room temperature under a hydrogen atmosphere. The reaction was filtered through Celite ® , washed with dimethylacetamide, then concentrated in vacuo. The resultant solid residue was washed with MeO, then dried to give 2-hydroxy-6-methoxybenzo[de]isoquinoline-1,3-dione (194 mg, 96%). mp 259-261°C. 1 H NMR (400 MHz, DMSO-d6) δH 10.63 (brs, 1H, O(17)H), 8.51 (app. ddd

LRMS: m/z(%)= 244

To a solution 5-hydroxy-benzo[de]isochromene-1,3-dione (100 mg. 0.46 mmol) in anhydrous acetone (5mL), SO4Me2 (0.8 ml, 0.93 mmol) and K2CO3 (200 mg

The resultant precipitate was filtered, washed with H2O and dried to give 5-methoxybenzo[de]isochromene-1,3-dione (78 mg, 74%) as a cream solid 3 . 1 H NMR (400 MHz, DMSO-d6) δH 8.42 (dd, J = 8.3, 1.1 Hz, 1H, C(2)H), 8.35 (dd

Hydroxy-5-methoxy-benzo

hydroxylamine hydrochloride (45 mg, 0.66 mmol) was added. The reaction mixture was stirred under reflux for 1 h under inert atmosphere. The reaction mixture was then diluted with cold H2O (75 mL); the precipitate was then filtered, washed with H2O and dried to give 2-hydroxy-5-methoxy-benzo[de]isoquinoline-1,3-dione (81 mg, 97%) as a yellow solid 3 . nmax: 3658

CH3); 13 C NMR (101 MHz, DMSO-d6)

mmol) and O-benzylhydroxylamine hydrochloride (8.6 g, 54.0 mmol) in anhydrous THF (50 mL), was added triethylamine (7.5 mL, 54.0 mmol). The reaction mixture was stirred under reflux for 3 h under an inert atmosphere, then concentrated in vacuo. The crude product was purified using flash column chromatography (10-30% EtOAc in cyclohexane

)H), 7.60-7.53 (m, 2H, OBn(11) ArH2)

1 mmol) and triphosgene (1.35 g, 4.5 mmol) in anhydrous THF (40 mL) at 0 °C, TEA (1.26 mL, 9.0 mmol) was added dropwise. The reaction mixture was stirred for 2 h at room temperature under an atmosphere, then concentrated in vacuo

EtOAc in cyclohexane). 3-Benzyloxyquinazoline-2,4-dione (726 mg, 66%) was obtained as a white solid 4 . 1 H NMR (400 MHz, DMSO-d6) δH 11.44 (s, 1H, N(8)H)

DMSO-d6)

Hydroxyquinazoline-2,4-dione (8)

10 (wt/wt) %) was added. The reaction mixture was stirred for 2 h under H2 atmosphere, then filtered through Celite ® , then concentrated in vacuo to give 3-hydroxyquinazoline-2,4-dione (28 mg, 87%) as a white solid 4 . 1 H NMR (400 MHz

089 mmol) was added. The reaction mixture was stirred at 80 °C for 2 h, then quenched with cold H2O (75mL); the resultant precipitate was collected by filtration, washed with water, and dried. 1-Benzyl-3-benzyloxyquinazoline-2,4-dione (256 mg, 95%) was obtained as a white solid

OBn(12) ArH5, (C(16)H)2, (C(17)H)2, (C(18)H)), 7.11 (d, J = 8

Benzyl-3-hydroxyquinazoline-2

The reaction mixture was then concentrated in vacuo, dissolved in DMF (0.5 mL), poured onto to cold H2O (50 mL); precipitate was then filtered off and washed with minimal amount of cold CH2Cl2 to give 1-benzyl-3-hydroxyquinazoline-2,4-dione (51 mg, 28%) 5 . 1 H NMR (400 MHz, DMSO-d6) δH 10.86 (s, 1H, O(12)H), 8.09 (dd

Hydroxy-2-thioxo-2,3-dihydroquinazolin-4-one (11)

thiophosgene (100 µL, 1.3 mmol) were added dropwise. The reaction mixture was stirred at room temperature overnight, then diluted with H2O (15 mL), extracted with CH2Cl2 (3 × 15 mL); the combined organic extracts were washed with brine (20 mL), dried over Na2SO4 then concentrated in vacuo. Crude methyl 2-isothiocyanatobenzoate was then added to solution of hydroxylamine hydroxyl (82 mg, 1.18 mmol) and sodium hydroxide

The reaction mixture was stirred for 2h at room temperature, precipitate was filtered off

DMSO-d6) δH 12.97 (s, 1H, N(10)H), 11.24 (s, 1H, O(13)H), 7.98 (d, J = 8.0 Hz, 1H, C(6)H), 7.75 (t, J = 7.9 Hz, 1H C(2)H)

DMSO-d6)

High-throughput production of human proteins for crystallization: the SGC experience

Site-directed mutagenesis by inverse PCR

The synthesis of (±)-xanthorrhoein

3-Hydroxy-1H-quinazoline-2,4-dione as a New Scaffold To Develop Potent and Selective Inhibitors of the Tumor-Associated Carbonic Anhydrases IX and XII

3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integrase

3-Hydroxy-and 3-alkoxy-2-sulfanylquinazolin-4(3H)-ones: synthesis and reactions with alkylating and acylating agents

Image to ImageJ: 25 years of image analysis

The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability

(c) Nsp14-nsp10 was docked with compounds within a grid box encompassing the full surface. The affinities of binding modes were calculated for each compound and grouped based on predicted ???activities. The colouring reflects the location of binding mode on the structure of nsp14-nsp10; dashed line describes the median of affinities in this cohort. Three or more gels were analysed for each inhibitor. Some data was excluded due to user determined factors such as: the quality of the gel being insufficient to obtain satisfactory data (e.g. gel cracked during drying), the signal of the radiation was below a minimum threshold, or the controls run on the gel were of unsatisfactory quality (e.g.bands running in a non-horizontal, or "smiling" format).

DSF experiments were carried out using the method of Niesen et al 8